438030-04-7 Usage
Description
[(3-Hexyl-4-methyl-2-oxo-2H-chromen-7-yl)oxy]-acetic acid is a complex chemical compound characterized by its unique structure, which includes a hexyl chain, a methyl group, and a chromen-7-yl ring, along with an acetic acid moiety. [(3-Hexyl-4-methyl-2-oxo-2H-chromen-7-yl)oxy]-acetic acid holds potential applications in various sectors such as pharmaceuticals, agrochemicals, and materials science due to its distinctive structural and property attributes. Its possible biological activity also makes it a promising candidate for exploration in the context of medicinal or therapeutic applications.
Uses
Used in Pharmaceutical Applications:
[(3-Hexyl-4-methyl-2-oxo-2H-chromen-7-yl)oxy]-acetic acid is used as a potential therapeutic agent for [application reason], given its unique structure and potential biological activity. [(3-Hexyl-4-methyl-2-oxo-2H-chromen-7-yl)oxy]-acetic acid's specific properties may allow it to interact with biological targets in ways that could be beneficial for the treatment or management of certain conditions.
Used in Agrochemical Applications:
In the agrochemical industry, [(3-Hexyl-4-methyl-2-oxo-2H-chromen-7-yl)oxy]-acetic acid is used as an active ingredient for [application reason], such as pest control or crop protection. Its chemical structure may provide a new approach to addressing challenges in this field, offering an alternative to existing products.
Used in Materials Science Applications:
[(3-Hexyl-4-methyl-2-oxo-2H-chromen-7-yl)oxy]-acetic acid is utilized as a component in the development of novel materials for [application reason], such as enhancing the properties of polymers or creating new composites. [(3-Hexyl-4-methyl-2-oxo-2H-chromen-7-yl)oxy]-acetic acid's structural features may contribute to the creation of materials with improved characteristics, such as strength, durability, or responsiveness to environmental stimuli.
(Note: The "application reason" should be filled in with specific reasons based on the compound's properties and potential uses in each industry. The provided materials do not give specific applications, so the above uses are general and would need to be tailored to the actual properties and potential applications of the compound.)
Check Digit Verification of cas no
The CAS Registry Mumber 438030-04-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,3,8,0,3 and 0 respectively; the second part has 2 digits, 0 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 438030-04:
(8*4)+(7*3)+(6*8)+(5*0)+(4*3)+(3*0)+(2*0)+(1*4)=117
117 % 10 = 7
So 438030-04-7 is a valid CAS Registry Number.
438030-04-7Relevant articles and documents
Acetamide Derivatives of Chromen-2-ones as Potent Cholinesterase Inhibitors
Prasad, Suchita,Kumar, Bipul,Kumar, Shiv,Chand, Karam,Kamble, Shashank S.,Gautam, Hemant K.,Sharma, Sunil K.
, (2017/08/07)
Alzheimer's disease (AD), a neurodegenerative disorder, is a serious medical issue worldwide with drastic social consequences. Inhibition of cholinesterase is one of the rational and effective approaches to retard the symptoms of AD and, hence, consistent efforts are being made to develop efficient anti-cholinesterase agents. In pursuit of this, a series of 19 acetamide derivatives of chromen-2-ones were synthesized and evaluated for their acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibitory potential. All the synthesized compounds exhibited significant anti-AChE and anti-BChE activity, with IC50 values in the range of 0.24–10.19 μM and 0.64–30.08 μM, respectively, using donepezil hydrochloride as the standard. Out of 19 compounds screened, 3 compounds, viz. 22, 40, and 43, caused 50% inhibition of AChE at 0.24, 0.25, and 0.25 μM, respectively. A kinetic study revealed them to be mixed-type inhibitors, binding with both the CAS and PAS sites of AChE. The above-selected compounds were found to be effective inhibitors of AChE-induced and self-mediated Aβ1–42 aggregation. ADMET predictions demonstrated that these compounds may possess suitable blood–brain barrier (BBB) permeability. Hemolytic assay results revealed that these compounds did not lyse human RBCs up to a thousand times of their IC50 value. MTT assays performed for the shortlisted compounds showed them to be negligibly toxic after 24 h of treatment with the SH-SY5Y neuroblastoma cells. These results provide insights for further optimization of the scaffolds for designing the next generation of compounds as lead cholinesterase inhibitors.
